MDSpire - Summary
Feature

Metformin’s Potential Role in Posterior Capsule Opacification

Common diabetes therapy reaches intraocular lens tissue and may help limit PCO, says newly published data

  • March 30, 2026

  • 3 min

Share

Recent laboratory studies in the British Journal of Ophthalmology reveal metformin, a commonly prescribed antidiabetic medication, may play an unexpected role in reducing the risk of posterior capsule opacification (PCO) after cataract surgery. PCO occurs in 20-30% of patients within five years of surgery, and while Nd:YAG laser capsulotomy is a treatment option, it has associated risks. Research conducted on 20 patients with diabetes showed that metformin reaches the lens capsule and correlates with reduced LEC proliferation, suggesting it may alter PCO risk profiles linked to diabetes.

Original Source(s)

Metformin’s Potential Role in Posterior Capsule Opacification

  • March 30, 2026

Related Content

Decoding Idiopathic Intracranial Hypertension

Marc Bouffard discusses Mass General Brigham’s recently launched initiative aimed at better understanding idiopathic intracranial hypertension

Farid Takes Helm of Aurion MAB

Aurion Biotech names Marjan Farid chair of medical advisory board

  • March 27, 2026

  • 2 min
Why Proactive Dry Eye Care Should Be the New Standard

The dental profession long ago decided it was important to preach preventative maintenance for everyone. We should do the same